BUDIMEX SA logo

BUDIMEX SA (BDXP)

Market Open
4 Dec, 14:50
WSE WSE
612. 60
+8
+1.32%
- Market Cap
- P/E Ratio
3.8% Div Yield
30,310 Volume
- Eps
604.6
Previous Close
Day Range
600.6 612.6
Year Range
438.8 677.6
Want to track BDXP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days

Summary

BDXP trading today higher at zł612.6, an increase of 1.32% from yesterday's close, completing a monthly decrease of -2.08% or zł13. Over the past 12 months, BDXP stock gained 28.97%.
BDXP pays dividends to its shareholders, with the most recent payment made on Sep 30, 2025. The next announced payment will be in In 3 weeks on Dec 31, 2025 for a total of zł1.05.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0.04%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports. The next scheduled earnings report is due on Feb 03, 2026.
BUDIMEX SA has completed 5 stock splits, with the recent split occurring on Apr 01, 2022.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).

BDXP Chart

Here's Why Becton Dickinson (BDX) is a Strong Value Stock

Here's Why Becton Dickinson (BDX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 week ago
BDX Unveils Portable PureWick System for On-the-Go Incontinence Care

BDX Unveils Portable PureWick System for On-the-Go Incontinence Care

BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.

Zacks | 3 weeks ago
Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript

Becton, Dickinson and Company (BDX) Q4 2025 Earnings Call Transcript

Becton, Dickinson and Company ( BDX ) Q4 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Adam Reiffe Thomas Polen - President, CEO & Chairman Christopher DelOrefice - Executive VP & CFO Conference Call Participants Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2383 for domestic calls and area code +1 402 220-7202 for international calls.

Seekingalpha | 4 weeks ago

BUDIMEX SA (BDXP) FAQ

What is the stock price today?

The current price is zł612.60.

On which exchange is it traded?

BUDIMEX SA is listed on NYSE.

What is its stock symbol?

The ticker symbol is BDXP.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.8%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 3.24.

When is the next earnings date?

The next earnings report will release on Feb 03, 2026.

Has BUDIMEX SA ever had a stock split?

BUDIMEX SA had 5 splits and the recent split was on Apr 01, 2022.

BUDIMEX SA Profile

- Industry
- Sector
Thomas E. Polen Jr. CEO
WSE Exchange
US0758871091 ISIN
US Country
70,000 Employees
8 Dec 2025 Last Dividend
1 Apr 2022 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800